RECORD // Company

Inmune Bio Inc.

Formerly: Inmune Bio, Inc.

Built 2026-11-22T00:18:24Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (2)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Inmune Bio, Inc. · Ctgov · same registered legal name as 'Inmune Bio, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • INMUNE BIO, INC. · East licences · same registered legal name as 'Inmune Bio, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-05 · accession 0001213900-26-116359

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-4,722,0003 months ended 2026-09-3010-Q2026-11-050001213900-26-1163592026-11-22 00:18 UTCReport an error
Cash and cash equivalents$16,329,000at 2026-09-3010-Q2026-11-050001213900-26-1163592026-11-22 00:18 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001711754
Ticker
INMB
EIN
475205835
UEI
LWE3M1FM5BT8
CUSIP
45782T105
Record ID
sx:sec:0001711754

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

37 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-20SEC EDGAR company profile2026-11-22 00:18 UTCReport an error
SIC industry2836 Biological Products, (No Diagnostic Substances)2026-11-20SEC EDGAR company profile2026-11-22 00:18 UTCReport an error
State of incorporationNV2026-11-20SEC EDGAR company profile2026-11-22 00:18 UTCReport an error
Fiscal year end (MMDD)12312026-11-20SEC EDGAR company profile2026-11-22 00:18 UTCReport an error
Business address225 NE MIZNER BLVD, SUITE 640, BOCA RATON, FL, 334322026-11-20SEC EDGAR company profile2026-11-22 00:18 UTCReport an error
ExchangesNasdaq2026-11-20SEC EDGAR company profile2026-11-22 00:18 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$50,0002025-12-3110-K, XBRL Revenues2026-11-22 00:18 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-45,933,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 00:18 UTCReport an error
Total assets (at 2025-12-31)$32,351,0002025-12-3110-K, XBRL Assets2026-11-22 00:18 UTCReport an error
Stockholders' equity (at 2025-12-31)$23,524,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 00:18 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$24,751,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 00:18 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-22,582,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 00:18 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$1,042,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 00:18 UTCReport an error
Long-term debt (at 2024-12-31)$15,000,0002024-12-3110-K, XBRL LongTermDebt2026-11-22 00:18 UTCReport an error
Operating lease liabilities (at 2025-12-31)$1,034,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 00:18 UTCReport an error
Unrecorded purchase obligations (at 2024-12-31)$1,400,0002024-12-3110-K, XBRL UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount2026-11-22 00:18 UTCReport an error
Form D total offering amount (D filed 2019-05-10)$4,699,9042019-05-10D2026-11-22 00:18 UTCReport an error
Form D total amount sold (D filed 2019-05-10)$4,699,9042019-05-10D2026-11-22 00:18 UTCReport an error
Form D industry groupBiotechnology2019-05-10D2026-11-22 00:18 UTCReport an error
Form D revenue rangeDecline to Disclose2019-05-10D2026-11-22 00:18 UTCReport an error
Form D date of first sale2019-04-292019-05-10D2026-11-22 00:18 UTCReport an error
8-K Item 1.01 (filed 2026-10-29)Entry into a Material Definitive Agreement. Securities Purchase Agreement On October 27, 2026, INmune Bio Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a single investor (the “Purchaser”), pursuant to which the Company agreed to issue and sell to the Purchaser, in a registered direct offering (the “Registered Direct Offering”), 3,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at an offering price of $1.50 per share. In a concurrent private placement (the “Private Placement” and, together with the Registered Direct Offering, the “Offering”), the Company also agreed to issue to…2026-10-29SEC EDGAR 8-K 0001213900-26-113535 (text as filed, excerpt)2026-11-22 00:18 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-10-29)On October 28, 2026, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information contained in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.2026-10-29SEC EDGAR 8-K 0001213900-26-113535 (text as filed, excerpt)2026-11-22 00:18 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-10-21)INmune Bio Inc. (the “Company”) has prepared a slide deck that the Company intends to use in presentations from time to time (the “Presentation”). The Presentation is furnished as Exhibit 99.3 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.3 of this Current Report on Form 8-K is furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Exhibit 99.3 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act…2026-10-21SEC EDGAR 8-K 0001213900-26-111207 (text as filed, excerpt)2026-11-22 00:18 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-10-21)On October 21, 2026, the Company issued two press releases related to Ebstrocel™, the Company’s allogeneic stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB), announcing that the Company (i) has entered into a Master Services Agreement with Uniphar Durbin Ireland Limited (“Uniphar”) establishing a scalable framework to support international access, distribution and commercialization of Ebstrocel™, and (ii) has submitted its pre-Marketing Authorisation Application (pre-MAA) package to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Ebstrocel™ (CORDStrom™). Copies of the press releasees are attached as Exhibits 99.1 and 99.2 to this Current Report…2026-10-21SEC EDGAR 8-K 0001213900-26-111207 (text as filed, excerpt)2026-11-22 00:18 UTCReport an error
Largest institutional holder #1 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$1,151,4712026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #2 (13F as filed): AQR CAPITAL MANAGEMENT LLC$1,079,4162026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #3 (13F as filed): BlackRock, Inc.$507,9302026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #4 (13F as filed): RAYMOND JAMES FINANCIAL INC$347,1822026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #5 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$310,2812026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #6 (13F as filed): GOLDMAN SACHS GROUP INC$301,9492026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #7 (13F as filed): MILLENNIUM MANAGEMENT LLC$260,0812026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #8 (13F as filed): SUSQUEHANNA INTERNATIONAL GROUP, LLP$258,2772026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #9 (13F as filed): JANE STREET GROUP, LLC$218,7982026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #10 (13F as filed): UBS Group AG$179,9732026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Federal award transactions, fiscal year 2026 (this one registration only)$-1,950,4212026-09-30USAspending recipient profile2026-11-22 00:18 UTCReport an error
Number of federal award transactions, fiscal year 2026 (this one registration only)22026-09-30USAspending recipient profile2026-11-22 00:18 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.